Ensysce Biosciences: files financials and pro forma for Cy Biopharma

What happened Ensysce Biosciences filed Amendment No. 2 to its Form 8-K on Oct 16, 2026 reporting that it filed financial statements and pro forma information related to Cy Biopharma. The filing says the audited consolidated financial statements of Cy Biopharma as of and for the years ended Dec 31, 2025 and Dec 31, 2024 are filed as Exhibit 99.3, the unaudited condensed consolidated financial statements as of and for the six months ended Jun 30, 2026 and Jun 30, 2025 are filed as Exhibit 99.4, and the unaudited pro forma condensed combined financial statements are filed as Exhibit 99.5 to this Amendment No. 2 and incorporated herein by reference.

Key details

• Audited consolidated financial statements of Cy Biopharma for the years ended Dec 31, 2025 and Dec 31, 2024 are filed as Exhibit 99.3.
• Unaudited condensed consolidated financial statements of Cy Biopharma for the six months ended Jun 30, 2026 and Jun 30, 2025 are filed as Exhibit 99.4.
• Unaudited pro forma condensed combined balance sheet as of Jun 30, 2026 and pro forma statements of operations for the six months ended Jun 30, 2026 and the year ended Dec 31, 2025 are filed as Exhibit 99.5.
• The exhibits list also includes Consent of EisnerAmper LLP as Exhibit 23.1, a business overview as Exhibit 99.1, and risk factors as Exhibit 99.2.

Why it may matter The filing reports Item 9.01 (financial statements and exhibits), which covers historical audited and unaudited financial statements of Cy Biopharma and unaudited pro forma condensed combined financial information for the transaction described in the original 8-K. This filing does not show why the insider traded or why the company acted.